Cellectar Preferred Stock Total Equity from 2010 to 2024
| CLRB Stock | USD 1.58 0.02 1.28% |
Preferred Stock Total Equity | First Reported 2011-06-30 | Previous Quarter 11.7 M | Current Value 8.6 M | Quarterly Volatility 3.8 M |
Check Cellectar Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cellectar Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 288.9 K, Interest Expense of 363.4 K or Selling General Administrative of 11.3 M, as well as many indicators such as Dividend Yield of 0.46, Days Sales Outstanding of 0.0 or Invested Capital of 0.0. Cellectar financial statements analysis is a perfect complement when working with Cellectar Biosciences Valuation or Volatility modules.
Cellectar | Preferred Stock Total Equity |
Latest Cellectar Biosciences' Preferred Stock Total Equity Growth Pattern
Below is the plot of the Preferred Stock Total Equity of Cellectar Biosciences over the last few years. It is Cellectar Biosciences' Preferred Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cellectar Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Preferred Stock Total Equity | 10 Years Trend |
|
Preferred Stock Total Equity |
| Timeline |
Cellectar Preferred Stock Total Equity Regression Statistics
| Arithmetic Mean | 7,525,845 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 136.64 | |
| Mean Deviation | 9,295,045 | |
| Median | 995,782 | |
| Standard Deviation | 10,283,140 | |
| Sample Variance | 105.7T | |
| Range | 24.2M | |
| R-Value | 0.86 | |
| Mean Square Error | 30.2T | |
| R-Squared | 0.74 | |
| Significance | 0.000044 | |
| Slope | 1,971,348 | |
| Total Sum of Squares | 1480.4T |
Cellectar Preferred Stock Total Equity History
About Cellectar Biosciences Financial Statements
Cellectar Biosciences stakeholders use historical fundamental indicators, such as Cellectar Biosciences' Preferred Stock Total Equity, to determine how well the company is positioned to perform in the future. Although Cellectar Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cellectar Biosciences' assets and liabilities are reflected in the revenues and expenses on Cellectar Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cellectar Biosciences. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Preferred Stock Total Equity | 23 M | 24.2 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cellectar Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cellectar Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cellectar Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cellectar Biosciences Stock:Check out the analysis of Cellectar Biosciences Correlation against competitors. For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectar Biosciences. If investors know Cellectar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cellectar Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.41) | Return On Assets (1.66) | Return On Equity (7.97) |
The market value of Cellectar Biosciences is measured differently than its book value, which is the value of Cellectar that is recorded on the company's balance sheet. Investors also form their own opinion of Cellectar Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cellectar Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cellectar Biosciences' market value can be influenced by many factors that don't directly affect Cellectar Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cellectar Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cellectar Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cellectar Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.